Powered by

IBM to wind down Watson's work in AI-based drug discovery: report

Apr 18, 2019 - FierceBiotech
Board and Executive Moves

IBM is ending new sales its Watson programs aimed at artificial intelligence-based drug discovery and development due to poor financial returns, according to a report from Stat.

The news follows Big Blue's decisions last year to move away from offering Watson in hospital management settings, not to mention the departure of the general manager of the division's health-focused unit last October.

IBM has previously rolled out some high-profile partnerships, though not entirely in drug d...